Perrigo Company Plc  (PRGO)
Other Ticker:  
Price: $30.7500 $-0.12 -0.389%
Day's High: $31 Week Perf: 1.05 %
Day's Low: $ 30.53 30 Day Perf: 7.67 %
Volume (M): 2,406 52 Wk High: $ 40.28
Volume (M$): $ 73,972 52 Wk Avg: $34.14
Open: $30.61 52 Wk Low: $26.81

 Market Capitalization (Millions $) 4,210
 Shares Outstanding (Millions) 137
 Employees -
 Revenues (TTM) (Millions $) 4,654
 Net Income (TTM) (Millions $) 135
 Cash Flow (TTM) (Millions $) 130
 Capital Exp. (TTM) (Millions $) 91

Perrigo Company Plc
Perrigo Company PLC is an Irish-based international pharmaceutical and consumer health company that produces a wide range of prescription drugs, generic drugs, and over-the-counter (OTC) consumer healthcare products. The company is headquartered in Dublin, Ireland, and has operations in over 30 countries around the world. Perrigo Company PLC is considered to be one of the largest manufacturers of private label OTC pharmaceutical products in the world.


Perrigo Company PLC was first established in 1887 as a small grocery store in Allegan, Michigan. In the early 1900s, the company expanded into the manufacture of prescription drugs and vitamins. In the 1980s, Perrigo began manufacturing private label OTC medications, which became the cornerstone of its business.

In 2013, the company acquired Elan Corporation, a biotechnology company headquartered in Irish. The acquisition allowed Perrigo to move its tax domicile to Ireland, a move that became controversial and absorbed considerable public attention.


Perrigo Company PLC's products are available in various forms, including tablets, capsules, creams, liquids, sprays, and gels. The company produces a wide range of products, including prescription medications, generic drugs, and OTC consumer healthcare products. Some of its most popular brands include Prevacid (a proton pump inhibitor for the treatment of acid reflux), Rogaine (a hair growth stimulant), and Claritin (an allergy medication).

Perrigo also manufactures private label products for retailers and other companies, including Walmarts and Target store brands. Some of the most popular OTC products that the company produces for retailers include pain relievers, cold and cough medications, and vitamins.

Organizational Structure

Perrigo Company PLC's organizational structure consists of several business units, including Consumer Healthcare Americas, Consumer Healthcare International, Rx Pharmaceuticals, and Specialty Science. The Consumer Healthcare Americas unit is responsible for the development, manufacture, and distribution of OTC consumer healthcare products in North and South America. The Consumer Healthcare International unit is responsible for the development, manufacture, and distribution of OTC products in Europe, Australia, and other international markets.

The Rx Pharmaceuticals unit is responsible for the development and manufacture of prescription, generic, and specialty drugs. The Specialty Sciences unit is responsible for the development of over-the-counter and prescription healthcare products for specialty healthcare communities.

Financial Information

Perrigo Company PLC is a publicly traded company listed on the New York Stock Exchange under the symbol "PRGO." As of June 2021, the company had a market cap of approximately $5 billion. In 2020, the company reported revenue of $5.1 billion, with the majority of its revenue coming from its Consumer Healthcare business units. The company's net income in 2020 was $261 million.


In recent years, Perrigo Company PLC has been the subject of several controversies related to its products and business practices. Some of the most notable controversies include a recall of its ranitidine product (a medication used to treat GERD and peptic ulcers) due to potential contamination, lawsuits related to the company's pricing practices, and a $1.9 billion tax liability dispute with the Irish government. The company has denied any wrongdoing in each of these cases.

   Company Address: The Sharp Building, Dublin 2, 0
   Company Phone Number: 7094000   Stock Exchange / Ticker: NYSE PRGO
   PRGO is expected to report next financial results on February 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.

China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023

China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.

Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance

The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.

Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period

Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.


Perrigo Plc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com